PrednisoneVincristineCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsGlucocorticoidsTreatment OutcomeAnemia, RefractoryDoxorubicinRefractory Period, ElectrophysiologicalProcarbazineImmunosuppressive AgentsDrug Administration ScheduleAntibodies, Monoclonal, Murine-DerivedPrednisoloneAzathioprineMechlorethamineDrug Therapy, CombinationMelphalanMitoxantroneRemission InductionRecurrenceAnti-Inflammatory AgentsLymphoma, Non-HodgkinAnemia, Refractory, with Excess of BlastsThalidomideHodgkin DiseaseMethotrexateSalvage TherapyBleomycinMultiple MyelomaEtoposideFollow-Up StudiesCyclosporineColor TherapyChlorambucilLymphoma, Large B-Cell, DiffuseAdministration, OralDisease-Free SurvivalTime FactorsSurvival AnalysisAdrenal Cortex HormonesMycophenolic AcidVinblastineBoronic AcidsCombined Modality TherapyAsparaginasePyrazinesSurvival RateDose-Response Relationship, DrugMethylprednisoloneAntineoplastic AgentsCytarabineRetrospective StudiesDrug Resistance, NeoplasmAntibodies, MonoclonalKidney TransplantationThrombocytopeniaTacrolimusCarmustineProspective StudiesDexamethasonePrognosisInfusions, IntravenousGraft RejectionDrug ResistanceTreatment FailureLymphoma, FollicularClinical Trials as TopicPrecursor Cell Lymphoblastic Leukemia-LymphomaNephrotic SyndromeTransplantation, AutologousTaxoidsCyclosporinsDouble-Blind Method6-MercaptopurineVidarabineProstatic NeoplasmsAntirheumatic AgentsMaximum Tolerated DoseVindesineImmunologic FactorsEstramustinePolymyalgia RheumaticaEtiocholanoloneAntineoplastic Agents, HormonalArthritis, RheumatoidImmunosuppressionLymphoma, B-CellChronic DiseaseDisease ProgressionLomustineCladribinePulse Therapy, DrugDrug EvaluationAndrostenolsHematologic DiseasesLymphomaDacarbazineGraft SurvivalSeverity of Illness Index